On February 13, Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The transaction was valued at a total of $499,072, with each share ...

Ronald E. Blaylock, a director at Pfizer Inc. (NYSE:PFE), purchased 19,457 shares of the company's common stock. The ...

Pfizer Inc. (NYSE:PFE – Get Free Report) was the target of some unusual options trading activity on Friday. Stock traders ...

Shareholders are set to convene in April at Pfizer’s annual meeting to vote on the company’s director seats for the year. A Starboard-backed director—or two—would have given the investor ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Pfizer announced Jeffrey Legos, PhD, MBA as its new chief oncology officer. Bluejay Therapeutics announced Mary Cromwell, PhD, has joined its leadership team as SVP and head of technical operations.

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

Persistent levels of spike protein from COVID-19 vaccines could be associated with a range of chronic symptoms like excessive ...

A total of 22,558 indigent children in Lanao del Sur will benefit from the Bangsamoro Autonomous Region in Muslim Mindanao ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

Pfizer PFE reported fourth-quarter 2024 adjusted ... of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.